Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:brand
gptkb:drug |
| gptkbp:activeIngredient |
gptkb:peginterferon_alfa-2b
|
| gptkbp:approvalYear |
2001
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:L03AB10
|
| gptkbp:chemicalClass |
gptkb:insulin
|
| gptkbp:combinationTherapy |
ribavirin
|
| gptkbp:contraindication |
autoimmune hepatitis
severe liver dysfunction |
| gptkbp:eliminationHalfLife |
30-54 hours
|
| gptkbp:form |
pegylated interferon
|
| https://www.w3.org/2000/01/rdf-schema#label |
PEG-Intron
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Merck_&_Co.
|
| gptkbp:marketedIn |
gptkb:Europe
gptkb:United_States |
| gptkbp:mechanismOfAction |
immunotherapy
antiviral |
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
gptkb:depression
gptkb:anemia fatigue flu-like symptoms |
| gptkbp:usedFor |
gptkb:hepatitis_C
|
| gptkbp:bfsParent |
gptkb:Enzon_Pharmaceuticals
|
| gptkbp:bfsLayer |
7
|